Should healthy people over 70 take a statin?
The benefit in this trial was small, and it did not add healthy years. Among 9,971 Australians aged 70 and older, a daily statin meant about 23 fewer heart and stroke events per 1,000 people over roughly six years, but it did not help them stay alive and free of dementia or disability.
Whether a statin is worth taking after 70, for someone who has never had heart trouble, has been an open question. The STAREE trial set out to answer it. Researchers recruited people living in their own homes through general practices across Australia. None had a history of cardiovascular disease, diabetes, or dementia. Their average age was about 75, and 51.9% were women. Half took atorvastatin 40 mg once a day, and half took an identical dummy pill (placebo).
The trial had two main goals. The first was major cardiovascular events: death from heart or blood vessel disease, a nonfatal heart attack or stroke, or a procedure to reopen blocked heart arteries. The second was disability-free survival, meaning staying alive without dementia or lasting physical disability.
What the statin trial in people over 70 found
After a median of 5.9 years, 297 of 4,984 people on atorvastatin (6.0%) had a major cardiovascular event, compared with 412 of 4,987 on placebo (8.3%). That is an absolute drop of 2.3 percentage points, or 60 versus 83 people per 1,000. Put another way, about 43 people had to take the statin for roughly six years for one of them to avoid an event. In relative terms, the risk was about 30% lower (hazard ratio 0.70), very likely somewhere between 18% and 39% lower. There is less than a 1 in 1,000 chance that gap was coincidence.
The second main result did not budge. Death from any cause, dementia, or persistent physical disability occurred in 637 people on the statin (12.8%) and 676 on placebo (13.6%). That works out to about 6% lower risk (hazard ratio 0.94), a gap small enough to be chance (p = 0.25). The true effect could plausibly be anything from 16% lower to 5% higher.
Dr. Kumar’s Take
A 30% relative drop sounds large. In absolute terms, 6.0% of people on the statin had an event, compared with 8.3% on placebo. One event avoided for every 43 people taking a pill every day for about six years is a modest return.
The second result carries more weight for this age group. Disability-free survival tracks whether people stayed alive and free of dementia and persistent physical disability. A statin that lowers cardiovascular events without moving that measure is not changing the bigger picture.
My view is that statins are applied far too widely, and that the strongest case for them is in people who already have cardiovascular disease. Nobody in this trial did, and the results do not change that view. They do give older adults an honest set of numbers to weigh, which leads to the side effects.
Side effects and limits of the STAREE trial
Serious side effects were uncommon and equal in both groups: 131 people on atorvastatin (2.7%) and 129 on placebo (2.7%). Milder problems were not equal. Muscle problems, liver problems, and diabetes-related problems were all more common in the statin group. For someone taking a pill for years to prevent an event that may never happen, those side effects count.
The trial itself was well built. It was large, randomized, and double-blind, so neither the participants nor the researchers knew who got the real drug. Its limits are about who it covers. Everyone was 70 or older, lived in Australia, and had no cardiovascular disease, diabetes, or dementia, so the results do not apply to people with those conditions. It also tested a single statin at a single dose.
Practical Takeaways
- If you are over 70 with no heart disease and a statin comes up, ask for the absolute numbers: in this trial, it meant about 23 fewer major cardiovascular events per 1,000 people over roughly six years.
- Keep the second result in view, because the statin did not help people stay alive and free of dementia or lasting physical disability.
- If you take a statin, tell your doctor about new muscle aches and ask about checking your blood sugar and liver, since muscle, liver, and diabetes-related problems were more common on atorvastatin.
- Do not stop a statin you already take without talking to your doctor, especially if you have heart disease, diabetes, or a past stroke, because this trial did not include people with those conditions.
Related Studies and Research
- Does high LDL cholesterol help older people live longer? A review of 19 studies
- Does rosuvastatin prevent heart disease in people at intermediate risk? The HOPE-3 trial
- Can meditation help prevent heart attacks and strokes?
- HIIT helps older adults lose fat without losing muscle
FAQs
What does disability-free survival mean?
It is a way of measuring healthy lifespan rather than lifespan alone. In STAREE, a person lost disability-free survival if they died from any cause, developed dementia, or developed persistent physical disability. The idea is to capture what most older adults want from a preventive drug: more years that are both alive and independent. A drug can lower one kind of event without moving this measure, and that is what happened here.
Does this trial apply to people over 70 who already have heart disease or diabetes?
No. People with a history of cardiovascular disease, diabetes, or dementia were left out of STAREE on purpose, so its results say nothing direct about them. Someone who has already had a heart attack or stroke is in a different situation, and this trial was not designed to answer that question. People in those groups should weigh a statin with their own doctor rather than use these numbers as a guide.
Why didn’t fewer heart events lead to longer healthy lives?
The study authors offered one likely reason: 80% of the deaths in the trial were from non-cardiovascular causes. When most deaths come from other illnesses, preventing some heart attacks and strokes has limited room to change overall survival. The disability-free result also had a wide range. The statin’s true effect could sit anywhere from 16% lower to 5% higher, so the trial cannot rule out a small benefit or a small harm.
Bottom Line
In STAREE, 9,971 Australians aged 70 and older with no cardiovascular disease, diabetes, or dementia took atorvastatin 40 mg or a placebo for a median of 5.9 years. The statin lowered major cardiovascular events from 8.3% to 6.0%, one event avoided for every 43 people treated. It did not help people live longer free of dementia or disability, and muscle, liver, and diabetes-related side effects were more common. For healthy older adults, that is a small benefit to weigh against years of a daily pill and its side effects.
